[ad_1]
And according to what was reported by “The New York Times” on Wednesday, the vaccine reduces the spread of the virus by people who have been vaccinated.
Data indicates that the vaccine has achieved an overall efficacy rate of 72 percent in the United States.
She added that this vaccine has also shown high efficacy against the two mutated versions of the virus that have emerged in Britain and South Africa.
And the vaccine, in large-scale laboratory trials, has recorded efficacy against severe cases of 85.9% in the United States, 81.7% in South Africa and 87.6% in Brazil.
The authority added that the Johnson & Johnson vaccine, which can help speed up the vaccination process with one dose, not two, is safe to use.
The announcement marks another step towards the use of a third vaccine option in the United States, as independent advisers at the agency question whether there is strong enough evidence to recommend use.
In the meantime, the US Health Authority is expected to make its final decision on use within days.
The pace of vaccine distribution has been slower than expected, hampered by logistical affairs and poor weather conditions, as the United States has witnessed more than 500,000 deaths from the virus.
So far, about 65 million Americans have received at least one dose of Pfizer or Moderna vaccines, which require two doses several weeks apart for full protection.
Johnson & Johnson has tested its single-dose vaccine on 44,000 people in the United States, Latin America and South Africa.
Due to the spread of different mutated strains of the virus in several countries, the researchers geographically analyzed the test results.
The results of a first study showed that it was not necessary to transport patients to hospitals and that there were no deaths 28 days after receiving the vaccine.
[ad_2]
Source link
